<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03258554</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2017-01522</org_study_id>
    <secondary_id>NCI-2017-01522</secondary_id>
    <secondary_id>NRG-HN004</secondary_id>
    <secondary_id>NRG-HN004</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <nct_id>NCT03258554</nct_id>
  </id_info>
  <brief_title>Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin</brief_title>
  <official_title>Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Stage III-IVB Head and Neck Cancer With a Contraindication to Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II/III trial studies how well radiation therapy works with durvalumab
      or cetuximab in treating patients with stage III-IVB head and neck cancer who cannot take
      cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
      Monoclonal antibodies, such as durvalumab and cetuximab, may interfere with the ability of
      tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will
      work better than the usual therapy of radiation therapy with cetuximab in treating patients
      with head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety of radiotherapy (RT) with concurrent and adjuvant anti-PD-L1
      therapy (MEDI4736 [durvalumab]) is safe in patients with locoregionally advanced head and
      neck cancer (HNC) who have a contraindication to cisplatin. (Lead-in) II. To test the
      hypothesis that concurrent RT and anti-PD-L1 therapy improves progression free survival (PFS)
      compared to standard therapy (RT with concurrent cetuximab) in patients with locoregionally
      advanced HNC who have a contraindication to cisplatin. (Phase II) III. To test the hypothesis
      that concurrent RT and anti-PD-L1 therapy improves overall survival compared to standard
      therapy (RT with concurrent cetuximab) in patients with locoregionally advanced HNC who have
      a contraindication to cisplatin. (Phase III)

      SECONDARY OBJECTIVES:

      I. To compare toxicity using Common Terminology Criteria for Adverse Events (CTCAE) and
      Patient Reported Outcomes (PRO)-CTCAE between patients treated with RT + anti-PD-L1 therapy
      versus RT/cetuximab.

      II. To test the effect of anti-PD-L1 therapy in the subpopulation of patients with tumors
      that overexpress PD-L1.

      III. To compare overall survival, response (at 4-month fludeoxyglucose F-18 [FDG]-positron
      emission tomography [PET]-computed tomography [CT]), locoregional failure, distant
      metastasis, and competing mortality in the two arms by known risk factors, including p16
      status and omega score.

      IV. To test the hypothesis that MEDI4736 (durvalumab) therapy arm will have less decline in
      the physical function domain of European Organization for Research and Treatment of Cancer
      Core Questionnaire (EORTC QLQ-C30 version 3.0) based on the change in score from baseline to
      12 months from end of RT, compared to the cetuximab-RT arm in patients with locoregionally
      advanced HNC who have a contraindication to cisplatin.

      V. To test the hypothesis that MEDI4736 (durvalumab) therapy arm at 1 year (from end of RT)
      will have less decline in swallowing related quality of life (QOL) using the M. D. Anderson
      Dysphagia Inventory (MDADI) total composite score, based on the change in score from baseline
      to 12 months from end of RT, compared to the cetuximab-RT arm in patients who are medically
      unfit for cisplatin.

      VI. To compare swallowing related performance and function short and long term using the
      Performance Status Scale for Head &amp; Neck Cancer Patients (PSS-HN).

      VII. To evaluate gastrostomy tube retention rates between arms.

      TERTIARY OBJECTIVES:

      I. To test the hypothesis that radiation combined with MEDI4736 (durvalumab) enhances the
      adaptive immune response using three types of immunophenotyping compared to radiation
      combined with cetuximab.

      II. To compare overall QOL short term (end RT-8 months) and long term (12-24 months from end
      of RT) between arms using the EORTC QLQ-C30 version 3.0/HN35.

      III. To evaluate swallowing related QOL short term (end RT-8 months) and long term (12-24
      months from end of RT) using the EORTC Head and Neck (HN)35 swallowing domain and MDADI
      (subscales) between arms in patients with locoregionally advanced HNC who have a
      contraindication to cisplatin.

      IV. To evaluate patient reported fatigue using the fatigue items in the EORTC QLQ and
      PRO-CTCAE.

      V. To compare clinician and patient reported toxicity using CTCAE and PRO CTCAE.

      VI. To explore health utilities between cetuximab and MEDI4736 (durvalumab) RT using the
      European Quality of Life 5 Dimensional-5 Level (EQ5D-5L).

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive cetuximab intravenously (IV) over 120 minutes weekly. Treatment
      repeats every week for up to 8 courses in the absence of disease progression or unacceptable
      toxicity. Beginning 5-7 days after first cetuximab dose, patients undergo intensity modulated
      radiation therapy (IMRT) 5 fractions per week for up to 7 weeks.

      ARM II: Patients receive durvalumab IV over 60 minutes every 4 weeks. Treatment repeats every
      4 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity.
      Beginning week 2, patients undergo IMRT 5 fractions per week for up to 7 weeks.

      After completion of study treatment, patients are followed up at 1 month, every 4 months for
      1 year, every 6 months for 2 years, then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) defined as the occurrence of an adverse event (AE) during the specified observation window (Lead -in)</measure>
    <time_frame>Up to 4 weeks after radiation therapy</time_frame>
    <description>AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) (Phase II)</measure>
    <time_frame>From randomization until first evidence of local, regional, or distant disease progression or recurrence, or death from any cause, assessed up to 3 years</time_frame>
    <description>PFS will be estimated using the Kaplan-Meier method. The difference in PFS between the two arms will be tested using a log-rank test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS) (Phase III)</measure>
    <time_frame>From randomization until death from any cause, assessed up to 3 years</time_frame>
    <description>OS will be estimated using the Kaplan-Meier method. The difference in OS between the two arms will be tested using a log-rank test. Exploratory analysis adjusting for important factors such as age, site, Zubrod performance status, and clinical stages will be conducted using Cox models.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure (LRF)</measure>
    <time_frame>From randomization until first evidence of local, regional disease progression or recurrence, or death from study cancer or unknown causes, assessed up to 3 years</time_frame>
    <description>LRF will be estimated by cumulative incidence methods and compared using a cause-specific log-rank test. All failure times will be measured from the date of study randomization to the date of failure or last follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis (DM)</measure>
    <time_frame>From randomization until first evidence of distant metastasis, assessed up to 3 years</time_frame>
    <description>DM will be estimated by cumulative incidence methods and compared using a cause-specific log-rank test. All failure times will be measured from the date of study randomization to the date of failure or last follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Competing mortality</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be estimated by cumulative incidence methods and the effects of other covariates will be assessed using the Generalized Competing Event Model for Cancer Risk model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response on 4-month fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT), measured by Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>4 months</time_frame>
    <description>Response rates between the two arms will be compared using Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>Up to 180 days after the end of radiation therapy</time_frame>
    <description>The rates of adverse events will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Late toxicities &gt; 180 days after the end of radiation therapy. The rates of adverse events will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (QOL) analysis</measure>
    <time_frame>Baseline up to 12 months</time_frame>
    <description>Assessed using European Organization for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ)/Head-and-Neck module (H&amp;N35), EuroQol- 5 Dimension (EQ5D), M. D. Anderson Dysphagia Inventory (MDADI), patient reported outcomes (PRO)-CTCAE, geriatric screening (G8). The mean summary score of the EORTC QLQ/H&amp;N35, EQ5D, MDADI, PRO-CTCAE, G8, CCI, and the subscales will be determined. The mean change from baseline at each time point will be summarized using mean and standard deviations for each arm. Mean change from baseline will be compared between the arms using a two sample t test. If data normality assumptions are not met, the Wilcoxon rank sum test will be used to test the hypothesis. Mean change from baseline will be tested using an omnibus F test followed by individual comparisons of change scores at different time points within each treatment group. The same analysis will be conducted for between group comparisons at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in swallowing QOL using total composite M. D. Anderson Dysphagia Inventory (MDADI) score</measure>
    <time_frame>Baseline up to 1 year</time_frame>
    <description>The mean change from baseline at each time point will be summarized using mean and standard deviations for each arm. Mean change from baseline will be compared between the arms using a two sample t test. If data normality assumptions are not met, the Wilcoxon rank sum test will be used to test the hypothesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational research, including PD-L1 and p16</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Analyses of interaction between treatment arm and marker status will be done. Additionally toxicity for the two arms by marker status will be compared. Univariable and multivariable analysis will be performed using the Cox proportional hazards model for OS. Potential covariates evaluated for the multivariate models would be assigned treatment, age, Zubrod performance status, T-stage, N-stage, primary site, smoking history, other risk factors, as well as p16 and/PD-L1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Secondary biomarker analysis</measure>
    <time_frame>Baseline up to 1 month after last systemic dose</time_frame>
    <description>Will perform multiparametric flow cytometry on peripheral mononuclear cells (PBMC) from patient-derived blood samples to quantify changes in immune cell frequency and activation status before, during and after radiation combined with cetuximab or radiation combined with durvalumab. To assess the statistical significance of pre- to post-treatment changes in levels of immunoglobulin (Ig)Gs as well as other markers, normalized signal intensities (log2) will be tested using a paired t test within an arm and two sample t test between the two arms. If the distribution assumption is violated for the t tests, nonparametric tests, such as the Wilcoxon signed-rank test will be considered. Lastly, the association between PFS and OS and post-treatment changes in frequency and activation state of T-cells, clonality and diversity of T cell receptor (TCR), and IgG levels will be evaluated using a two-sided Wald test at 0.05 level on the basis of Cox models.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE)</measure>
    <time_frame>Up to 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>QOL endpoints using other items in EORTC QLQ/HN35, EQ5D and MDADI subscales</measure>
    <time_frame>Up to 12-24 months from end of RT</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">533</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Arm I (cetuximab, radiation therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive cetuximab IV over 120 minutes weekly. Treatment repeats every week for up to 8 courses in the absence of disease progression or unacceptable toxicity. Beginning 5-7 days after first cetuximab dose, patients undergo IMRT 5 fractions per week for up to 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (durvalumab, radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive durvalumab IV over 60 minutes every 4 weeks. Treatment repeats every 4 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients undergo IMRT 5 fractions per week for up to 7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (cetuximab, radiation therapy)</arm_group_label>
    <other_name>Chimeric Anti-EGFR Monoclonal Antibody</other_name>
    <other_name>Chimeric MoAb C225</other_name>
    <other_name>Chimeric Monoclonal Antibody C225</other_name>
    <other_name>Erbitux</other_name>
    <other_name>IMC-C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (durvalumab, radiation therapy)</arm_group_label>
    <other_name>Imfinzi</other_name>
    <other_name>Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer</other_name>
    <other_name>MEDI-4736</other_name>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Arm I (cetuximab, radiation therapy)</arm_group_label>
    <arm_group_label>Arm II (durvalumab, radiation therapy)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (cetuximab, radiation therapy)</arm_group_label>
    <arm_group_label>Arm II (durvalumab, radiation therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (cetuximab, radiation therapy)</arm_group_label>
    <arm_group_label>Arm II (durvalumab, radiation therapy)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (cetuximab, radiation therapy)</arm_group_label>
    <arm_group_label>Arm II (durvalumab, radiation therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIA

          -  Patients must have pathologically confirmed, previously untreated, unresected squamous
             cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, or carcinoma of
             unknown head/neck primary within 60 days prior to step 1 registration; submission of
             hematoxylin and eosin (H&amp;E) stained slides and formalin-fixed and paraffin-embedded
             (FFPE) tissue block (or punch biopsy of FFPE block) to the biospecimen bank at
             University of California, San Francisco (UCSF) for central review for oropharyngeal
             and unknown primaries and for p16 analysis for all other non- oropharyngeal primaries
             is mandatory for all patients; investigators should check with their pathology
             department regarding release of biospecimens before approaching patients about
             participation in the trial; for oropharyngeal and unknown primaries, submission of H&amp;E
             and p16 stained slides to the biospecimen bank at UCSF for central review is also
             required prior to step 2 registration

               -  Note: fine needle aspirates (FNA) samples are not acceptable since they do not
                  provide enough material for PD-L1 and p16 testing

          -  Patients must have stage III-IVB head and neck squamous cell carcinoma (HNSCC)
             (American Joint Committee on Cancer [AJCC] seventh [7th] edition) based on the
             following minimum diagnostic workup within 60 days prior to step 1 registration:

               -  General history and physical examination by a radiation oncologist, medical
                  oncologist, and/or ear, nose and throat (ENT) or head &amp; neck surgeon

               -  For larynx, hypopharynx, and base of tongue primaries, a laryngopharyngoscopy
                  (mirror and/or fiberoptic and/or direct procedure) is required, unless the
                  patient cannot tolerate or refuses

               -  Imaging of the head and neck with a neck CT or magnetic resonance imaging (MRI)
                  (with contrast, unless contraindicated) or PET/CT (with contrast, unless
                  contraindicated)

               -  Chest imaging: chest CT with and without contrast (unless contraindicated) or
                  PET/CT

          -  Patients must have a contraindication to cisplatin as defined in the following bullet
             points; sites must complete the online tool at comogram.org prior to step 1
             registration to determine if the patient is eligible; the scores must be recorded on a
             case report form (CRF)

               -  Age &gt;= 70 with moderate to severe comorbidity or vulnerability to cisplatin,
                  defined as having any one of the following conditions within 30 days prior to
                  step 1 registration:

                    -  Modified Charlson Comorbidity Index &gt;= 1

                    -  Adult Comorbidity Evaluation (ACE)-27 Index &gt;= 1

                    -  Generalized Competing Event Model for Cancer Risk (GCE) omega PFS score &lt;
                       0.60

                    -  Geriatric screening (G-8) score =&lt; 14

                    -  Cancer and Aging Research Group (CARG) toxicity score &gt;= 30%

                    -  Cumulative Illness Rating scale for Geriatrics (CIRS-G) score &gt;= 4 OR

               -  Age &lt; 70 with severe comorbidity or vulnerability to cisplatin, defined as having
                  two or more of the following conditions within 30 days prior to step 1
                  registration

                    -  Modified Charlson Comorbidity Index &gt;= 1

                    -  ACE-27 Index &gt;= 1

                    -  GCE omega PFS-score &lt; 0.60

                    -  G-8 score =&lt; 14

                    -  CARG Toxicity score &gt;= 30%

                    -  CIRS-G score &gt;= 4 OR

               -  Age &gt;= 18 with an absolute or relative contraindication to cisplatin, defined as
                  one or more of the following within 30 days prior to Step 1 registration:

                    -  Creatinine clearance (CC) &gt; 30 and &lt; 60 cc/min; for this calculation, use
                       the Cockroft-Gault formula

                    -  Zubrod performance status 2 prior to step 1 registration

                    -  Pre-existing peripheral neuropathy grade &gt;= 1

                    -  History of hearing loss, defined as either:

                         -  Existing need of a hearing aid OR

                         -  &gt;= 25 decibel shift over 2 contiguous frequencies on a pretreatment
                            hearing test

          -  Within 14 days prior to step 1 registration: Absolute neutrophil count (ANC) &gt;= 1,000
             cells/mm^3

          -  Within 14 days prior to step 1 registration: Platelets &gt;= 100,000 cells/mm^3

          -  Within 14 days prior to step 1 registration: Hemoglobin &gt;= 9.0 g/dl (Note: the use of
             transfusion or other intervention to achieve hemoglobin [Hgb] &gt;= 9.0 g/dl is
             acceptable)

          -  Within 14 days prior to step 1 registration: Aspartate aminotransferase (AST) or
             alanine aminotransferase (ALT) =&lt; 2.5 times institutional upper limit of normal

          -  Within 14 days prior to step 1 registration: Serum bilirubin =&lt; 1.5 x institutional
             upper limit of normal

          -  Within 14 days prior to step 1 registration: Measured creatinine clearance (CL) &gt; 30
             mL/min or calculated creatinine CL &gt; 30 mL/min by the Cockcroft-Gault formula
             (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of
             creatinine clearance

          -  For women of childbearing potential, a negative serum or urine pregnancy test within
             14 days prior to step 1 registration; Note: women will be considered post-menopausal
             if they have been amenorrheic for 12 months without an alternative medical cause; the
             following age-specific requirements apply:

               -  Women &lt; 50 years of age would be considered post-menopausal if they have been
                  amenorrheic for 12 months or more following cessation of exogenous hormonal
                  treatments and if they have luteinizing hormone and follicle-stimulating hormone
                  levels in the post-menopausal range for the institution or underwent surgical
                  sterilization (bilateral oophorectomy or hysterectomy)

               -  Women &gt;= 50 years of age would be considered post-menopausal if they have been
                  amenorrheic for 12 months or more following cessation of all exogenous hormonal
                  treatments, had radiation-induced menopause with last menses &gt; 1 year ago, had
                  chemotherapy-induced menopause with last menses &gt; 1 year ago, or underwent
                  surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or
                  hysterectomy)

          -  The patient or a legally authorized representative must provide study-specific
             informed consent prior to step 1 registration

          -  PRIOR TO STEP 2 REGISTRATION INCLUSION CRITERIA

          -  For patients with oropharyngeal or unknown primaries: p16 determination by
             immunohistochemistry (defined as greater than 70% strong nuclear or nuclear and
             cytoplasmic staining of tumor cells), confirmed by central pathology review

               -  Note: for patients with oral cavity, laryngeal, and hypopharyngeal primaries,
                  analysis of p16 status prior to step 2 registration/randomization is not required
                  (p16 status will be analyzed centrally post-hoc); step 2 registration for these
                  patients can be completed after step 1 registration

        Exclusion Criteria:

          -  PRIOR TO STEP 1 REGISTRATION EXCLUSION CRITERIA

          -  Prior invasive malignancy within the past 3 years (except for non-melanomatous skin
             cancer, and early stage treated prostate cancer)

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Prior immunotherapy

          -  Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy,
             or immune therapy for the study cancer

          -  Distant metastases

          -  If both of the following conditions are present, the patient is ineligible:

               -  &lt; 10 pack-year smoking history

               -  p16-positive carcinoma of the oropharynx or unknown primary that are T0-3, N0-2b
                  (AJCC 7th Edition)

                    -  Note: in the event that a registered patient has a p16-positive result on
                       central review with the tumor and nodal stage T0-3, N0-2b (AJCC 7th
                       Edition), then the site will be notified that the patient is ineligible

          -  Zubrod performance status &gt;= 3

          -  Patients with oral cavity cancer are excluded from participation if the patient is
             medically operable and resection of the primary tumor is considered technically
             feasible by an oral or head and neck cancers surgical subspecialist;(please consult
             the surgical oncology co-principal investigator [PI], Steven Chang, Doctor of Medicine
             [MD], if clarification is needed on an individual case)

          -  Within 14 days of step 1 registration, unless corrected prior to step 1 registration:
             Sodium &lt; 130 mmol/L or &gt; 155 mmol/L

          -  Within 14 days of step 1 registration, unless corrected prior to step 1 registration:
             Potassium &lt; 3.5 mmol/L or &gt; 6 mmol/L

          -  Within 14 days of step 1 registration, unless corrected prior to step 1 registration:
             Fasting glucose &lt; 40 mg/dl or &gt; 400 mg/dl

          -  Within 14 days of step 1 registration, unless corrected prior to step 1 registration:
             Serum calcium (ionized or adjusted for albumin) &lt; 7 mg/dl or &gt; 12.5 mg/dl

          -  Within 14 days of step 1 registration, unless corrected prior to step 1 registration:
             Magnesium &lt; 0.9 mg/dl or &gt; 3 mg/dl

          -  Unstable angina and/or congestive heart failure requiring hospitalization within 3
             months prior to step 1 registration

          -  Transmural myocardial infarction within 3 months prior to step 1 registration

          -  Respiratory illness requiring hospitalization at the time of step 1 registration

               -  Note: if the respiratory illness is resolved and the patient meets the
                  eligibility status above, then the patient can be considered for the trial

          -  Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires
             oxygen therapy or is thought to require oxygen therapy within 1 year prior to step 1
             registration

          -  Clinically apparent jaundice and/or known coagulation defects

          -  Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis, etc.])

               -  The following are exceptions to this criterion:

                    -  Patients with vitiligo or alopecia;

                    -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
                       hormone replacement;

                    -  Any chronic skin condition that does not require systemic therapy;

                    -  Patients without active disease in the last 5 years may be included but only
                       after consultation with the medical oncology study chair;

                    -  Patients with celiac disease controlled by diet alone

          -  History of active primary immunodeficiency including, but not limited to acquired
             immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and
             Prevention (CDC) definition; Note: human immunodeficiency virus (HIV) testing is not
             required for entry into this protocol; the need to exclude patients with AIDS from
             this protocol is necessary because the treatment involved in this protocol may be
             immunosuppressive; patients with known HIV, CD4 counts &gt;= 200/uL, and undetectable
             viral loads who are stable on an antiretroviral regimen may be included

          -  Current or prior use of immunosuppressive medication within 14 days before step 1
             registration, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone, or an equivalent corticosteroid

          -  Receipt of live attenuated vaccination within 30 days prior to step 1 registration

          -  Medical or psychiatric illness which would compromise the patient's ability to
             tolerate treatment or limit compliance with study requirements

          -  Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception during treatment and
             for 6 months after the last dose of cetuximab or MEDI14736 (durvalumab); this
             exclusion is necessary because the treatment involved in this study may be
             significantly teratogenic; women who are breastfeeding are also excluded

          -  Prior allergic reaction or hypersensitivity to cetuximab or MEDI4736 (durvalumab) or
             any of study drug excipients

          -  History of (non-infectious) pneumonitis that required steroids or current pneumonitis

          -  History of allogenic organ transplantation

          -  Uncontrolled hypertension

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled serious chronic gastrointestinal condition associated with diarrhea

          -  Active infection including tuberculosis (clinical evaluation that includes clinical
             history, physical examination and radiographic findings, and tuberculosis [TB] testing
             in line with local practice), hepatitis B (known positive hepatitis B virus [HBV]
             surface antigen [HBsAg] result), hepatitis C; patients with a past or resolved HBV
             infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence
             of HBsAg) are eligible; patients positive for hepatitis C (hepatitis C virus [HCV])
             antibody are eligible only if polymerase chain reaction is negative for HCV
             ribonucleic acid (RNA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loren Mell</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sachin G. Pai</last_name>
      <phone>251-445-9870</phone>
      <email>pfrancisco@usouthal.edu</email>
    </contact>
    <investigator>
      <last_name>Sachin G. Pai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center-North Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie E. Bauman</last_name>
      <phone>800-327-2873</phone>
    </contact>
    <investigator>
      <last_name>Julie E. Bauman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Arizona Medical Center-University Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie E. Bauman</last_name>
      <phone>520-626-9008</phone>
    </contact>
    <investigator>
      <last_name>Julie E. Bauman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagus Sampath</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Sagus Sampath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth M. Beadle</last_name>
      <phone>650-498-7061</phone>
      <email>ccto-office@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Beth M. Beadle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Medical Center Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penrose-Saint Francis Healthcare</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>308-398-6518</phone>
      <email>clinicaltrials@sfmc-gi.org</email>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McKee Medical Center</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keren Sturtz</last_name>
      <phone>303-777-2663</phone>
      <email>ccrp@co-cancerresearch.org</email>
    </contact>
    <investigator>
      <last_name>Keren Sturtz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen F Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory A. Masters</last_name>
      <phone>302-623-4450</phone>
      <email>KDempsey@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Gregory A. Masters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anterpreet S. Neki</last_name>
      <phone>904-202-7051</phone>
    </contact>
    <investigator>
      <last_name>Anterpreet S. Neki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan A. Faller</last_name>
      <phone>217-876-4740</phone>
      <email>rhamrick@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan A. Faller</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan A. Faller</last_name>
      <phone>217-788-3528</phone>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhao</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Yujie Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Hospital Randallia</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Y. Wang</last_name>
      <phone>260-373-8888</phone>
      <email>parkviewresearch@parkview.com</email>
    </contact>
    <investigator>
      <last_name>Sarah Y. Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center East</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih J. Wei</last_name>
      <phone>317-497-2823</phone>
      <email>lcheri@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Shih J. Wei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center South</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih J. Wei</last_name>
      <phone>317-497-2823</phone>
      <email>lcheri@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Shih J. Wei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center North</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih J. Wei</last_name>
      <phone>317-497-2823</phone>
      <email>lcheri@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Shih J. Wei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Behrens</last_name>
      <phone>515-241-6727</phone>
    </contact>
    <investigator>
      <last_name>Robert J. Behrens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavan S. Reddy</last_name>
      <phone>800-362-0070</phone>
      <email>Keisha.humphries@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Pavan S. Reddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne M. Arnold</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>Susanne M. Arnold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minh T. Truong</last_name>
      <phone>617-638-8265</phone>
    </contact>
    <investigator>
      <last_name>Minh T. Truong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis W. Nugent</last_name>
      <phone>781-744-8027</phone>
    </contact>
    <investigator>
      <last_name>Francis W. Nugent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis P. Worden</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Francis P. Worden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer InstituteDownriver</name>
      <address>
        <city>Brownstown</city>
        <state>Michigan</state>
        <zip>48183</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Macomb Hospital-Clinton Township</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>313-916-1784</phone>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford West Bloomfield Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>888-734-5322</phone>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Clinic North-Bemidgi</name>
      <address>
        <city>Bemidji</city>
        <state>Minnesota</state>
        <zip>56601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>218-333-5000</phone>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kalispell Regional Medical Center</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>406-969-6060</phone>
      <email>mccinfo@mtcancer.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory N. Gan</last_name>
      <phone>505-925-0366</phone>
      <email>LByatt@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Gregory N. Gan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafi Kabarriti</last_name>
      <phone>718-379-6862</phone>
      <email>sforde@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Rafi Kabarriti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roger Maris Cancer Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>701-234-6161</phone>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati/Barrett Cancer Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin P. Redmond</last_name>
      <phone>513-558-4553</phone>
      <email>uchealthnews@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin P. Redmond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yao</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Min Yao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo R. Bonomi</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Marcelo R. Bonomi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Pointe</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin P. Redmond</last_name>
      <email>clinicaltrials@ucphysicians.com</email>
    </contact>
    <investigator>
      <last_name>Kevin P. Redmond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. S. Thompson</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>J. S. Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willard G. Andrews</last_name>
      <phone>215-481-2402</phone>
    </contact>
    <investigator>
      <last_name>Willard G. Andrews</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NRG Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loren K. Mell</last_name>
      <phone>858-246-0471</phone>
      <email>lmell@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Loren K. Mell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center-Pelham</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abderrahim Khomani</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Abderrahim Khomani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abderrahim Khomani</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Abderrahim Khomani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>605-312-3320</phone>
      <email>OncologyClinicalTrialsSF@SanfordHealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Medical Center</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Collin D. Driscoll</last_name>
      <phone>608-775-2385</phone>
      <email>cancerctr@gundersenhealth.org</email>
    </contact>
    <investigator>
      <last_name>Collin D. Driscoll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UW Cancer Center at ProHealth Care</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy R. Wassenaar</last_name>
      <phone>262-928-5539</phone>
      <email>Chanda.miller@phci.org</email>
    </contact>
    <investigator>
      <last_name>Timothy R. Wassenaar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

